Blood immune cells as potential biomarkers predicting relapse-free survival of stage III/IV resected melanoma patients treated with peptide-based vaccination and interferon-alpha.

The only non significant P-value was relative to the production of 1 cytokine by CD8 + Melan-A + T cells, where the 2 patients with percentages higher than the cut-off showed a clear trend of long RFS but were lost early at follow-up ( Figure 4 ).

also in 10,213 other papers

An opposite tendency was observed in CD4 + T cells with EM phenotype, which showed a trend of increase in REL patients ( Figure 1B ).

also in 26,766 other papers